Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Merck
Moodys
McKesson

Last Updated: May 26, 2022

ALIQOPA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch® Generic Entry Outlook for Aliqopa

Aliqopa was eligible for patent challenges on September 14, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 29, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for ALIQOPA
International Patents:153
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 59
Clinical Trials: 15
Patent Applications: 680
Drug Prices: Drug price information for ALIQOPA
What excipients (inactive ingredients) are in ALIQOPA?ALIQOPA excipients list
DailyMed Link:ALIQOPA at DailyMed
Drug patent expirations by year for ALIQOPA
Drug Prices for ALIQOPA

See drug prices for ALIQOPA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ALIQOPA
Generic Entry Date for ALIQOPA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALIQOPA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NRG OncologyPhase 2
City of Hope Medical CenterPhase 1/Phase 2
Dana-Farber Cancer InstitutePhase 1/Phase 2

See all ALIQOPA clinical trials

US Patents and Regulatory Information for ALIQOPA

ALIQOPA is protected by four US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ALIQOPA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ALIQOPA

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Fused azole-pyrimidine derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES

FDA Regulatory Exclusivity protecting ALIQOPA

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ALIQOPA

When does loss-of-exclusivity occur for ALIQOPA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 09
Estimated Expiration: See Plans and Pricing

Argentina

Patent: 5718
Estimated Expiration: See Plans and Pricing

Australia

Patent: 12238891
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2013025549
Estimated Expiration: See Plans and Pricing

Canada

Patent: 32123
Estimated Expiration: See Plans and Pricing

Chile

Patent: 13002870
Estimated Expiration: See Plans and Pricing

China

Patent: 3649091
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 81534
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 130511
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0150138
Estimated Expiration: See Plans and Pricing

Cuba

Patent: 208
Estimated Expiration: See Plans and Pricing

Patent: 130133
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 16231
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 94508
Estimated Expiration: See Plans and Pricing

Dominican Republic

Patent: 013000223
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 13013006
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 3646
Estimated Expiration: See Plans and Pricing

Patent: 1391470
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 08525
Estimated Expiration: See Plans and Pricing

Patent: 94508
Estimated Expiration: See Plans and Pricing

Guatemala

Patent: 1300234
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 95907
Estimated Expiration: See Plans and Pricing

Israel

Patent: 8561
Estimated Expiration: See Plans and Pricing

Japan

Patent: 63834
Estimated Expiration: See Plans and Pricing

Patent: 26961
Estimated Expiration: See Plans and Pricing

Patent: 14510119
Estimated Expiration: See Plans and Pricing

Patent: 15164936
Estimated Expiration: See Plans and Pricing

Jordan

Patent: 58
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 9452
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 6057
Estimated Expiration: See Plans and Pricing

Patent: 13011583
Estimated Expiration: See Plans and Pricing

Montenegro

Patent: 021
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 014
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 6198
Estimated Expiration: See Plans and Pricing

Peru

Patent: 141038
Estimated Expiration: See Plans and Pricing

Poland

Patent: 94508
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 94508
Estimated Expiration: See Plans and Pricing

San Marino

Patent: 01500037
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 811
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 3595
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 94508
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1307105
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1937501
Estimated Expiration: See Plans and Pricing

Patent: 140021637
Estimated Expiration: See Plans and Pricing

Spain

Patent: 29653
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 49954
Estimated Expiration: See Plans and Pricing

Patent: 92158
Estimated Expiration: See Plans and Pricing

Patent: 1249847
Estimated Expiration: See Plans and Pricing

Patent: 1637656
Estimated Expiration: See Plans and Pricing

Tunisia

Patent: 13000401
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 1604
Estimated Expiration: See Plans and Pricing

Uruguay

Patent: 985
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ALIQOPA around the world.

Country Patent Number Title Estimated Expiration
Croatia P20150138 See Plans and Pricing
Eurasian Patent Organization 023646 ЗАМЕЩЁННЫЕ СОЛИ 2,3-ДИГИДРОИМИДАЗО[1,2-C]ХИНАЗОЛИНА (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-c]QUINAZOLINE SALTS) See Plans and Pricing
Hong Kong 1195907 取代的 -二氫咪唑並 喹唑啉鹽 (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS 23-[12-C]) See Plans and Pricing
European Patent Office 2508525 Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitués (Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts) See Plans and Pricing
Jordan 3147 مشتقات 2،3 - داي هيدرو إميدازو}1،2-{c كينازولين بها استبدال مفيدة لعلاج اضطرابات فرط التكاثر الخلوي والامراض المتعلق بتولد الاوعية (Substituted 2,3-dihydroimidazo[ 1,2- c] quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders And Diseases Associated with Angiogenesis) See Plans and Pricing
China 100384846 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Express Scripts
Baxter
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.